Skip to main content

Advertisement

Table 3 Early recurrence and treatment details in the low- and high-risk patients

From: Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study

Characteristics Low-risk patients High-risk patients
Long interval Short interval P Long interval Short interval P
(n = 84) (%) (n = 151) (%) (n = 48) (%) (n = 118) (%)
Intrahepatic tumor size (cm)    0.539    0.045
 Mean 2.0 ± 1.3 1.9 ± 1.3   3.5 ± 3.3 2.6 ± 2.1  
 Median 1.7 (1.3) 1.6 (1.0)   2.5 (1.9) 2.1 (1.3)  
Recurrence number    0.394    0.383
 1 44 (52.4) 86 (57.0)   13 (27.1) 38 (32.2)  
 2 12 (14.3) 21 (13.9)   4 (8.3) 14 (11.9)  
 3 4 (4.8) 5 (3.3)   0 9 (7.6)  
 > 3 20 (23.8) 29 (19.2)   20 (41.7) 41 (34.7)  
 Non-intrahepatic recurrence 4 (4.8) 10 (6.6)   11 (22.9) 16 (13.6)  
Recurrence location    0.686    0.755
 Intrahepatic recurrence 77 (91.7) 136 (90.1)   33 (68.8) 84 (71.2)  
 Distant metastasis 7 (8.3) 15 (9.9)   15 (31.3) 34 (28.8)  
  Lung 5 (6) 8 (5.3)   12 (25.0) 27 (22.9)  
  Bone 1 (1.2) 1 (0.7)   0 1 (0.8)  
  Others 1 (1.2) 6 (4.0)   3 (6.3) 6 (5.1)  
Recurrence BCLC stage (A, B and C)    0.580    0.280
 A 53 (63.1) 103 (68.2)   15 (31.3) 49 (41.5)  
 B 22 (26.2) 28 (18.5)   15 (31.3) 31 (26.3)  
 C 9 (10.7) 20 (13.2)   18 (37.5) 38 (32.2)  
Curative intent treatment for recurrence    0.430    0.388
 Yes 29 (34.5) 60 (39.7)   7 (14.6) 24 (20.3)  
 No 55 (65.5) 91 (60.3)   41 (85.4) 94 (79.7)  
Total treatment for recurrence (times)
 Resection 15 23   9 14  
 Ablation 38 124   23 76  
 LT 1 1   0 0  
 TACE 62 134   26 114  
 Radiotherapy 4 4   1 9  
  1. Values are presented as the median (interquartile range), mean (standard deviation), or n (%)
  2. BCLC Barcelona clinic liver cancer (stage), LT liver transplantation